216 related articles for article (PubMed ID: 22283844)
1. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
Horsley L; Marti K; Jayson GC
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
[TBL] [Abstract][Full Text] [Related]
2. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
3. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
[No Abstract] [Full Text] [Related]
4. Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.
Wu JM; Staton CA
Expert Opin Drug Discov; 2012 Aug; 7(8):723-43. PubMed ID: 22716277
[TBL] [Abstract][Full Text] [Related]
5. [Anticancer drugs under pressure].
Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
[TBL] [Abstract][Full Text] [Related]
6. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
7. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
Izzedine H
Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
10. Proteinuria and VEGF-targeted therapies:
an underestimated toxicity?
Izzedine H; Soria JC; Escudier B
J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
[TBL] [Abstract][Full Text] [Related]
11. Uncontrolled Hypertension and Oncology: Clinical Tips.
Kalaitzidis RG; Elisaf MS
Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
[TBL] [Abstract][Full Text] [Related]
12. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
[TBL] [Abstract][Full Text] [Related]
13. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
Eremina V; Quaggin SE
Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
[TBL] [Abstract][Full Text] [Related]
14. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
15. Intricacies of bevacizumab-induced toxicities and their management.
Gressett SM; Shah SR
Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
[TBL] [Abstract][Full Text] [Related]
16. Challenges for patient selection with VEGF inhibitors.
Longo R; Gasparini G
Cancer Chemother Pharmacol; 2007 Jul; 60(2):151-70. PubMed ID: 17370072
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
Ishak RS; Aad SA; Kyei A; Farhat FS
Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
[TBL] [Abstract][Full Text] [Related]
18. Novel targets for VEGF-independent anti-angiogenic drugs.
Petrillo M; Scambia G; Ferrandina G
Expert Opin Investig Drugs; 2012 Apr; 21(4):451-72. PubMed ID: 22339615
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic-induced hypertension: the molecular basis of signaling network.
Nagai A; Sado T; Naruse K; Noguchi T; Haruta S; Yoshida S; Tanase Y; Tsunemi T; Kobayashi H
Gynecol Obstet Invest; 2012; 73(2):89-98. PubMed ID: 22222493
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]